Manage Cookie Consent

This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you. To find out more, see our Terms & cookie policy

Pharmalytics Group provides expertise in strategic consulting, health technology assessment, and analytics to support pharmaceutical product commercialization.

Evidence Synthesis

Economic Modelling

Real-World Evidence
Generation

Market Access Strategy
& Analytics

Chak Balijepalli, MD, PhD

Founder, Managing Partner

Eric Druyts, MSc

Founder, Managing Partner

Gaye Siliman, PhD

Head of Statistics, Partner

Publications

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine.

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine.

On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?

On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?

Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and...

Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and...

Quality of Life in Wilson’s Disease: A Systematic Literature Review.

Quality of Life in Wilson’s Disease: A Systematic Literature Review.

Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs...

Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs...

The Impact of Digital Therapeutics on Current Health Technology Assessment Frameworks.

The Impact of Digital Therapeutics on Current Health Technology Assessment Frameworks.

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine.

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine.

On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?

On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?

Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and...

Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and...

Quality of Life in Wilson’s Disease: A Systematic Literature Review.

Quality of Life in Wilson’s Disease: A Systematic Literature Review.

Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs...

Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs...

The Impact of Digital Therapeutics on Current Health Technology Assessment Frameworks.

The Impact of Digital Therapeutics on Current Health Technology Assessment Frameworks.

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine.

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine.

On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?

On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?

Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and...

Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and...

Quality of Life in Wilson’s Disease: A Systematic Literature Review.

Quality of Life in Wilson’s Disease: A Systematic Literature Review.

0+

Reimbursement and health technology submissions

0+

Agencies
NICE, SMC, IQWiG, NOMA, HAS, CADTH, pCODR

0+

Therapeutic
areas

0+

Peer-reviewed publications

Testimonials

“An important strategic partner in reimbursement. Methodologists who understand the industry exceptionally well.”

Director, HEOR, small biotech

“Pharmalytics Group provided us with a strategic roadmap to seek reimbursement in several countries. They provided us with all the supporting scientific services, and educated us on methods behind the analyses performed. Their expertise and guidance was greatly appreciated. We will be sure to work with them again on our next indication.”

VP, Market Access, small biotech

“I have worked with the founders at Pharmalytics Group for more than a decade. They are a strategic, powerful pair at the height of their careers. Always a pleasure to work with.”

VP, Medical Affairs, top 5 pharma company

“Pharmalytics Group provides scientifically rigorous, high-quality research in a timely manner. The team is friendly and courteous. I highly recommend them to my colleagues working in HEOR and reimbursement.”

Executive Director, HEOR, top 5 pharma company

“An important strategic partner in reimbursement. Methodologists who understand the industry exceptionally well.”

Director, HEOR, small biotech

“Pharmalytics Group provided us with a strategic roadmap to seek reimbursement in several countries. They provided us with all the supporting scientific services, and educated us on methods behind the analyses performed. Their expertise and guidance was greatly appreciated. We will be sure to work with them again on our next indication.”

VP, Market Access, small biotech